{"id":935812,"date":"2026-02-10T16:44:38","date_gmt":"2026-02-10T21:44:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/"},"modified":"2026-02-10T16:44:38","modified_gmt":"2026-02-10T21:44:38","slug":"lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/","title":{"rendered":"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Feb.  10, 2026  (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on February 10, 2026, pursuant to the \u201cinducement grant\u201d exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Pazdera entering into employment with LB Pharmaceuticals.<\/p>\n<p>Dr. Pazdera received options to purchase 140,000 shares of LB Pharmaceuticals\u2019 common stock. The options carry a ten-year term and an exercise price per share equal to $24.22, which was the closing price of LB Pharmaceuticals\u2019 common stock on the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1\/48<sup>th<\/sup>\u00a0of the shares vesting monthly thereafter, subject to continuous service through the applicable vesting dates.<\/p>\n<p>\n        <strong>About LB-102<\/strong>\n      <\/p>\n<p>LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotics outside the U.S., LB-102 was developed to retain amisulpride\u2019s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. A Phase 2 clinical trial of LB-102 for bipolar depression is ongoing, and the Company expects to initiate a Phase 3 trial of LB-102 for schizophrenia in 1Q 2026, and a Phase 2 clinical trial for the adjunctive treatment of major depressive disorder in early 2027. Additional expansion opportunities for LB-102 include predominantly negative symptoms of schizophrenia, Alzheimer\u2019s disease psychosis and agitation, as well as other neuropsychiatric diseases.<\/p>\n<p>\n        <strong>About LB Pharmaceuticals<\/strong>\n      <\/p>\n<p>LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.<\/p>\n<p>\n        <strong>Media and Investor Contact<\/strong><br \/>\n        <br \/>Ellen Rose<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HINNDKLUfF2uRgaL0urkTJhO61p-Wv2LPNoKsDW8P4TzzgfLSkqgpZ6AWvZcDiQsPwl7gsAZPYRFPzLhzEN8fu9Tc5EurQiWLVTBZWFZs84=\" rel=\"nofollow\" target=\"_blank\">erose@lbpharma.us<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmRjYWJmNjItYWJlNS00NzAxLTg4OWUtODY2YzY2NTM0Y2ZhLTUwMDEzMDE5NS0yMDI2LTAyLTEwLWVu\/tiny\/LB-Pharmaceuticals-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on February 10, 2026, pursuant to the \u201cinducement grant\u201d exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Pazdera entering into employment with LB Pharmaceuticals. Dr. Pazdera received options to purchase 140,000 shares of LB Pharmaceuticals\u2019 common stock. The options carry a ten-year term and an exercise price per share equal to $24.22, which was &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935812","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on February 10, 2026, pursuant to the \u201cinducement grant\u201d exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Pazdera entering into employment with LB Pharmaceuticals. Dr. Pazdera received options to purchase 140,000 shares of LB Pharmaceuticals\u2019 common stock. The options carry a ten-year term and an exercise price per share equal to $24.22, which was &hellip; Continue reading &quot;LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T21:44:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-02-10T21:44:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/\"},\"wordCount\":443,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/\",\"name\":\"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==\",\"datePublished\":\"2026-02-10T21:44:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/","og_locale":"en_US","og_type":"article","og_title":"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on February 10, 2026, pursuant to the \u201cinducement grant\u201d exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Pazdera entering into employment with LB Pharmaceuticals. Dr. Pazdera received options to purchase 140,000 shares of LB Pharmaceuticals\u2019 common stock. The options carry a ten-year term and an exercise price per share equal to $24.22, which was &hellip; Continue reading \"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-10T21:44:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-02-10T21:44:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/"},"wordCount":443,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/","name":"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==","datePublished":"2026-02-10T21:44:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQwOCM3NDE5NzUyIzUwMDEzMDE5NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935812"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935812\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}